Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344462 | PMC |
| http://dx.doi.org/10.1093/eurjpc/zwab096 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Salt substitute recommendations for heart failure patients may influence guideline-directed medical therapies titration.
ESC Heart Fail
August 2024
Hôpital Sainte Musse, CHITS, Toulon, France.
Article Synopsis
- The study investigates the use of salt substitutes (saltSubs) for managing sodium intake in patients with chronic heart failure (CHF) in France, focusing on healthcare professional (HCP) recommendations and patient consumption.
- Only 13% of HCPs recommended saltSubs, while 17% of patients and 22% of caregivers reported using them, with those recommended showing a recent hospitalization for acute heart failure.
- The findings revealed that patients advised to use saltSubs were less likely to follow guideline-directed medical therapies (GDMTs), particularly angiotensin-converting enzyme inhibitors and related medications, indicating a potential conflict between saltSubs and standard CHF treatments.
Evaluation of Antiemetic Consistency in Chemotherapy-Induced Nausea and Vomiting Among NHL Patients in Sana'a, Yemen.
Int J Gen Med
May 2024
Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Background: Chemotherapy-induced nausea and vomiting (CINV) is a prevalent and distressing adverse effect that can negatively affect a patient's quality of life and treatment adherence.
Purpose: This study aimed to evaluate the consistency of antiemetic use with standard guidelines and to examine the factors influencing it.
Methods: This cross-sectional study was conducted at the National Oncology Center (NOC) of Al-Jomhouri Teaching Hospital, Sana'a, Yemen, from November 2022 to September 2023.
The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure: Position paper from the Cardiorenal Working Groups of the Spanish Society of Nephrology and the Spanish Society of Cardiology.
Clin Kidney J
May 2022
Centro de Investigación Biomédica en Red de las Enfermedades Cardiovasculares, Carlos III Institute of Health, Madrid, Spain.
Despite the high prevalence of chronic kidney disease (CKD) and its high cardiovascular risk, patients with CKD, especially those with advanced CKD (stages 4-5 and patients on kidney replacement therapy), are excluded from most cardiovascular clinical trials. It is particularly relevant in patients with advanced CKD and heart failure (HF) who have been underrepresented in many pivotal randomized trials that have modified the management of HF. For this reason, there is little or no direct evidence for HF therapies in patients with advanced CKD and treatment is extrapolated from patients without CKD or patients with earlier CKD stages.
View Article and Find Full Text PDFCharacteristics of warfarin under-prescription in older adults with atrial fibrillation.
Int J Cardiol Heart Vasc
December 2021
Division of Cardiology, Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.
Background: The prevalence of atrial fibrillation (AF) and atrial flutter (AFl) increases with age. Under-prescription of anticoagulants in older adults can lead to increased morbidity and mortality. We analyzed warfarin prescription patterns in older adults.
View Article and Find Full Text PDFUnder-prescription of direct oral anticoagulants for treatment of non-valvular atrial fibrillation and venous thromboembolism in the COVID-19 lockdown period.
Eur J Prev Cardiol
March 2022
Italian Medicines Agency, Rome, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!